Seropositivity of hepatitis B e antigen and hepatocellular carcinoma
- PMID: 15181977
- DOI: 10.1080/07853890310021580
Seropositivity of hepatitis B e antigen and hepatocellular carcinoma
Abstract
Chronic infection with hepatitis B virus (HBV) is an important clinical problem due to its worldwide distribution and potential of adverse sequelae including hepatocellular carcinoma (HCC). Hepatitis B e antigen (HBeAg) is a biomarker of active viral proliferation in hepatocytes and infectivity. The prevalence of HBeAg among subjects chronically infected with HBV decreases with the increase in age. Case series studies have found a lowest seroprevalence of HBeAg in HCC patients compared with patients affected with chronic hepatitis B and liver cirrhosis. Case-control studies have shown a significantly higher seroprevalence of HBeAg in HCC cases than matched controls. A recent long-term follow-up study has shown a significantly elevated HCC risk for seropositives of both hepatitis B surface antigen (HBsAg) and HBeAg compared with seropositives of HBsAg only and seronegatives. The biological gradient remained in further stratification analyses by serum level of alanine transaminase and status of liver cirrhosis detected by ultrasonography. The cumulative HCC risk from age 30 to 70 years has been estimated to be 87% for those who were persistently seropositive on HBsAg and HBeAg, 12% for those with persistent seropositivity of HBsAg only, and 1% for those who were seronegative on HBsAg and HBeAg.
Similar articles
-
Natural History of Chronic Hepatitis B Virus Infection in Ahvaz City, Iran.Asian Pac J Cancer Prev. 2018 Aug 24;19(8):2125-2129. doi: 10.22034/APJCP.2018.19.8.2125. Asian Pac J Cancer Prev. 2018. PMID: 30139211 Free PMC article.
-
Natural history of chronic hepatitis B REVEALed.J Gastroenterol Hepatol. 2011 Apr;26(4):628-38. doi: 10.1111/j.1440-1746.2011.06695.x. J Gastroenterol Hepatol. 2011. PMID: 21323729 Review.
-
Hepatitis B core-related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinoma.J Viral Hepat. 2019 Dec;26(12):1473-1480. doi: 10.1111/jvh.13191. Epub 2019 Sep 2. J Viral Hepat. 2019. PMID: 31418973
-
What can we learn from hepatitis B virus clinical cohorts?Liver Int. 2015 Jan;35 Suppl 1:91-9. doi: 10.1111/liv.12716. Liver Int. 2015. PMID: 25529093 Review.
-
Hepatitis B e antigen and the risk of hepatocellular carcinoma.N Engl J Med. 2002 Jul 18;347(3):168-74. doi: 10.1056/NEJMoa013215. N Engl J Med. 2002. PMID: 12124405
Cited by
-
AASLD guidelines for treatment of chronic hepatitis B.Hepatology. 2016 Jan;63(1):261-83. doi: 10.1002/hep.28156. Epub 2015 Nov 13. Hepatology. 2016. PMID: 26566064 Free PMC article. No abstract available.
-
The Complex Role of HBeAg and Its Precursors in the Pathway to Hepatocellular Carcinoma.Viruses. 2023 Mar 27;15(4):857. doi: 10.3390/v15040857. Viruses. 2023. PMID: 37112837 Free PMC article. Review.
-
Prevalence of hepatitis B e antigen in chronic HBV carriers in North-central Nigeria.J Health Popul Nutr. 2012 Dec;30(4):377-82. doi: 10.3329/jhpn.v30i4.13289. J Health Popul Nutr. 2012. PMID: 23304903 Free PMC article.
-
The Hepatitis B Virus Pre-Core Protein p22 Activates Wnt Signaling.Cancers (Basel). 2020 May 31;12(6):1435. doi: 10.3390/cancers12061435. Cancers (Basel). 2020. PMID: 32486480 Free PMC article.
-
DNA-guided hepatitis B treatment, viral load is essential, but not sufficient.World J Gastroenterol. 2009 Jan 28;15(4):423-30. doi: 10.3748/wjg.15.423. World J Gastroenterol. 2009. PMID: 19152446 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
